–Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 –Significant and clinically meaningful reductions in liver fat, alanine aminotransferase…